0001209191-20-016095.txt : 20200304 0001209191-20-016095.hdr.sgml : 20200304 20200304163053 ACCESSION NUMBER: 0001209191-20-016095 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200302 FILED AS OF DATE: 20200304 DATE AS OF CHANGE: 20200304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Walker Neal CENTRAL INDEX KEY: 0001604457 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 20687617 MAIL ADDRESS: STREET 1: 15 NEW ENGLAND EXECUTIVE PARK CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-02 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001604457 Walker Neal C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 1 1 0 0 President and CEO Common Stock 2020-03-02 4 M 0 96150 A 1025053 D Common Stock 2020-03-02 4 F 0 27623 1.26 D 997430 D Common Stock 2020-03-02 4 M 0 52564 A 1049994 D Common Stock 2020-03-02 4 F 0 15101 1.26 D 1034893 D Restricted stock units 2020-03-02 4 M 0 96150 0.00 D Common Stock 96150 288450 D Employee Stock Option (Right to Buy) 1.26 2020-03-02 4 A 0 255552 0.00 A 2030-03-01 Common Stock 255552 255552 D Restricted stock units 2020-03-02 4 A 0 146029 0.00 A Common Stock 146029 146029 D Restricted stock units 2020-03-02 4 A 0 73015 0.00 A Common Stock 73015 73015 D Restricted stock units 2020-03-02 4 A 0 52564 0.00 A Common Stock 52564 52564 D Restricted stock units 2020-03-02 4 M 0 52564 0.00 D Common Stock 52564 0 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date. The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest immediately. /s/ Mark Ballantyne, Attorney-in-fact 2020-03-04